Avidity Biosciences, a biopharmaceutical company developing a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs), today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation to AOC 1044.
Evonik has opened a new GMP facility to manufacture lipids for advanced pharmaceutical drug delivery applications, which is situated at the company’s site in Hanau, Germany.
EdiGene Biotechnology USA has moved into a new Research & Development Center in Waltham, Mass. to advance its proprietary LEAPER tech into in vivo RNA editing therapies: with an initial focus on ophthalmology and the central nervous system.
Lonza is to increase the size of the cell and gene therapy (CGT) development space at its Houston facility; the expansion will include viral vector-based process development and analytical development laboratories.
Yapan Bio, a contract development and manufacturing organization (CDMO) based in India, says it can now support end-to-end development and manufacturing of RNA, DNA and gene therapy products starting from plasmids.
A push toward multimodal businesses is encouraging greater reliance on contract development and manufacturing organizations (CDMOs), finds a new report.
Merck and Orna Therapeutics have announced a collaboration agreement to discover, develop and commercialize Orna’s next generation oRNA technology across multiple programs, including vaccines and therapeutics in infectious disease and oncology.
US biotech, CAMP4 Therapeutics, has secured US$100m in a Series B financing round that it says will be used to accelerate expansion of its regulatory RNA (regRNA) platform.
CDMO CordenPharma has increased its xRNA capabilities at its sterile injectable facility in Caponago, Italy: with a €10m ($10.7m) investment in new Lipid Nanoparticle (LNP) formulation, development and production areas.
eTheRNA Manufacturing, a specialist RNA process developer and manufacturing member of the eTheRNA group, has introduced a new lipid nanoparticle (LNP) formulation, development and production service.
Nutcracker Therapeutics, a biotech developing RNA therapeutics using its proprietary biochip-based manufacturing platform, has raised $167m in Series C financing: allowing it to expand and advance its pipeline of mRNA medicines for cancer and further...
The selected companies, the inaugural cohort for MassBioDrive, get to participate in an eight-week program focused on growing businesses and advancing breakthrough science.
Lipid nanoparticle systems (LNPs) as a delivery mechanism for novel drug modalities are proving effective, but there are bioanalytical challenges associated with encapsulation, says an expert.
Australia’s Noxopharm has in-licensed novel RNA tech developed by Hudson Institute of Medical Research: focusing on RNA drug discovery and mRNA vaccine manufacture via Noxopharm’s subsidiary Pharmorage.
As capital project delivery ramps back up to pre-pandemic levels over the coming months and years, the smaller biopharma players are looking outside their own resources for strategic manufacturing and research support, confirms a new market outlook from...
A new report reveals that “speed-to-market” has jumped up from a lower-ranking business driver before the pandemic to the top priority today for biopharma companies, overtaking cost-based considerations by a healthy margin.
The new facility will be home to Precision NanoSystems’s new global headquarters and include multiple GMP suites for manufacturing RNA therapeutics and vaccines.
To accelerate Covid-19 vaccine development, as well as upscale domestic manufacturing capabilities, the German government has announced a €750m (US$890m) fund to support the vaccine programs of three German developers, BioNTech, CureVac and IDT Biologika....
Renaissance BioScience enters a partnership with Mitacs to test its yeast-based, RNAi production platform for biocontrol and biotherapeutics applications.
Roche has renewed its interest in gene silencing drugs, paying $250m (€187m) for Santaris Pharma including its ‘antisense’ Locked Nucleic Acid (LNA) platform.
Bayer has inked a deal with preclinical CRO Cenix BioScience to use its genome-scale RNA interference (RNAi) platform to target an undisclosed disease.
New research could make it possible for scientists to use silicon particles as an effective drug delivery system that enables fragile small interfering RNA (siRNA) based drugs to be directly transported to the disease’s location.
MDRNA’s liposomal drug delivery formulation, DiLA2, lost no potency when stored for 12 months in conditions ranging from -80ºC to 4ºC, helping to validate it for administration of UsiRNA.
Agilent Technologies is expanding its nucleic acid active
pharmaceutical ingredient (API) manufacturing facility in Boulder,
Colorado, US, as the industry gravitates towards the
development of oligonucleotide-based drugs.
Sigma-Aldrich has continued its push into the RNAi field with the
launch of its new mirPremier miRNA (microRNA) isolation kit that
promises to speed up miRNA preparation while removing all large,
unwanted RNA.
Kreatech has launched the first complete miRNA isolation and
labelling kit, which combines the upstream isolation of small RNA
and the reagents necessary to label these DNA samples for
microarray analysis, offering a more complete...
US scientists have shown that microRNA (miRNA) plays an essential
role in the development of the fruit fly. The discovery means that
miRNA could emerge as a new target for interventions aimed at
treating disease, or as a therapeutic...
